Screener
Gyre Therapeutics, Inc. GYRE Q2 2026 earnings
Reported August 7, 2026 · Before market open
Revenue$29.1MBeat by $2.6M
EPS-$0.12Miss by $0.06
Revenue estimate$26.5M
EPS estimate-$0.06
“I am very pleased with Gyre's progress over this last quarter, the highlights of which include the acquisition of Cullgen with its robust degrader pipeline and strong executive team, the NMPA acceptance of an NDA for F351 for CHB liver fibrosis, Gyre's second major product candidate after ETUARYTM, and increased sales from our Gyre Pharmaceuticals division, which demonstrates our commercialization capabilities.”
Next report
Nov 6, 2026 (in 2 months)Revenue estimate$28.4M
EPS estimate-$0.15
Valuation & ratios
Segments
Versus estimates
Revenue
Diluted EPS
FAQ
- When did Gyre Therapeutics, Inc. report Q2 2026 earnings?
- Gyre Therapeutics, Inc. (GYRE) reported Q2 2026 earnings on August 7, 2026 before market open.
- What were Gyre Therapeutics, Inc.'s Q2 2026 revenue and EPS?
- Gyre Therapeutics, Inc. reported revenue of $29.1M and eps of $-0.12 for Q2 2026.
- Did Gyre Therapeutics, Inc. beat estimates in Q2 2026?
- Revenue beat the consensus estimate of $26.5M by $2.6M. EPS missed the consensus estimate of $-0.06 by $0.06.
- How did Gyre Therapeutics, Inc.'s Q2 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue grew 8.7% from $26.8M a year earlier.
- Where can I find Gyre Therapeutics, Inc.'s Q2 2026 SEC filings?
- You can read the 8-K earnings release (0001193125-26-339223) and the 10-Q periodic report (0001193125-26-340448) directly on SEC EDGAR. The filing index links above go to sec.gov.
